CD63 Polyclonal Antibody

$HepG2 cells probed with CD63\/MLA1 Polyclonal Antibody, Unconjugated (bs-1523R) at 1:100 for 30 minutes followed by incubation with a conjugated secondary (PE Conjugated) (green) for 30 minutes compared to control cells (blue), secondary only (light blue) and isotype control (orange).$

HepG2 cells probed with CD63\/MLA1 Polyclonal Antibody, Unconjugated (bs-1523R) at 1:100 for 30 minutes followed by incubation with a conjugated secondary (PE Conjugated) (green) for 30 minutes compared to control cells (blue), secondary only (light blue) and isotype control (orange).

$Lane 1: A431 lysates; Lane 2: HL-60 lysates; Lane 3: MCF-7 lysates; Lane 4: U97MG lysates probed with Anti \u2013(Name) Polyclonal Antibody, Unconjugated (Catalog #) at 1:300 overnight at 4˚C. Followed by a conjugated secondary antibody at 1:5000 for 90 min at 37˚C.$

Lane 1: A431 lysates; Lane 2: HL-60 lysates; Lane 3: MCF-7 lysates; Lane 4: U97MG lysates probed with Anti \u2013(Name) Polyclonal Antibody, Unconjugated (Catalog #) at 1:300 overnight at 4˚C. Followed by a conjugated secondary antibody at 1:5000 for 90 min at 37˚C.

$A549 cells(black) were fixed with 4% PFA for 10min at room temperature,permeabilized with 90% ice-cold methanol for 20 min at -20\u2103, and incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with CD63\/MLA1 Polyclonal Antibody(bs-1523R)at 1:50 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2% BSA in PBS, followed by secondary antibody(blue) incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).$

A549 cells(black) were fixed with 4% PFA for 10min at room temperature,permeabilized with 90% ice-cold methanol for 20 min at -20\u2103, and incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with CD63\/MLA1 Polyclonal Antibody(bs-1523R)at 1:50 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2% BSA in PBS, followed by secondary antibody(blue) incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).

Applications

WB
ELISA
FCM
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)

Reactivity

Human

Overview
Catalog #	bs-1523R
Product Name	CD63 Polyclonal Antibody
Applications	WB, ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human CD63
Clonality	Polyclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	967
Swiss Prot	P08962
Subcellular location	Cytoplasm, Cell membrane
Synonyms	MLA1; ME491; LAMP-3; OMA81H; TSPAN3; CD63 antigen; Granulophysin; Lysosomal-associated membrane protein 3; Melanoma-associated antigen ME491; Ocular melanoma-associated antigen; Tetraspanin-3; Tspan-3; CD63
Background	Functions as cell surface receptor for TIMP1 and plays a role in the activation of cellular signaling cascades. Plays a role in the activation of ITGB1 and integrin signaling, leading to the activation of AKT, FAK/PTK2 and MAP kinases. Promotes cell survival, reorganization of the actin cytoskeleton, cell adhesion, spreading and migration, via its role in the activation of AKT and FAK/PTK2. Plays a role in VEGFA signaling via its role in regulating the internalization of KDR/VEGFR2. Plays a role in intracellular vesicular transport processes, and is required for normal trafficking of the PMEL luminal domain that is essential for the development and maturation of melanocytes. Plays a role in the adhesion of leukocytes onto endothelial cells via its role in the regulation of SELP trafficking. May play a role in mast cell degranulation in response to Ms4a2/FceRI stimulation, but not in mast cell degranulation in response to other stimuli.
Application Dilution
WB	1:300-5000
ELISA	1:500-1000
FCM	1:20-100
IHC-P	1:200-400
IHC-F	1:100-500
IF(IHC-P)	1:50-200
IF(IHC-F)	1:50-200
IF(ICC)	1:50-200